| Autor: |
Kamil, Chwojnicki, Dorota, Iwaszkiewicz-Grześ, Anna, Jankowska, Maciej, Zieliński, Paweł, Łowiec, Mateusz, Gliwiński, Małgorzata, Grzywińska, Kamil, Kowalczyk, Aleksandra, Konarzewska, Paulina, Glasner, Justyna, Sakowska, Julia, Kulczycka, Anna, Jaźwińska-Curyłło, Marlena, Kubach, Bartosz, Karaszewski, Walenty, Nyka, Edyta, Szurowska, Piotr, Trzonkowski |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 35(1) |
| ISSN: |
1179-190X |
| Popis: |
Multiple sclerosis (MS) is an immune-mediated disease in which autoimmune T conventional (TWe present the results of a phase 1b/2a, open-label, two-arm clinical trial in 14 patients treated with autologous TNo severe adverse events were observed. Self-assessed quality of life (EuroQol-5 Dimensions [EQ-5D] form) did not change and did not differ significantly between the groups. A total of 12 relapses were noted in five intravenously treated patients, who had from one to three attacks per year. Three out of ten participants who completed the trial in the IV group deteriorated more than 1 point on the Expanded Disability Status Scale (EDSS) during the follow-up. At the same time, no patients in the IT group experienced a relapse or such a deterioration in the EDSS. No significant differences were found in the Multiple Sclerosis Functional Composite (MSFC) scale in both the IV and IT groups. Magnetic resonance imaging (MRI) scans revealed a significantly lower change in the T2 lesion volume in the IT group compared to the IV group. The increase in the number of new T2 lesions during the follow-up was significant for the IV group only. There were no significant changes in the level of TNo serious adverse events were reported in the 14 patients with MS treated with TEudraCT: 2014-004320-22; registered 18 November 2014. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink